ALKS: Alkermes plc

ALKS Nouvelles

• Seeking Alpha 21:08 Alkermes: A More Than Solid Quarter (NASDAQ:ALKS)
• Investing 16:18 Alkermes stock price target raised to $42 from $40 at RBC Capital
• Zacks 14:23 Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
• Investing 20:26 Alkermes stock price target lowered to $33 by BofA on growth outlook
• Zacks 13:30 Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
• The Motley Fool 12:28 Alkermes Q2 Sales Up 14 Percent
• Zacks 12:25 Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
• Investing 11:18 Alkermes shares rise 5% as Q2 earnings, revenue beat expectations
• Investing 11:08 Alkermes Plc earnings beat by $0.16, revenue topped estimates
• Zacks 14:36 CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
• Zacks 12:46 Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
• Zacks 16:10 Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
• Zacks 14:53 Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
• Zacks 14:00 GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
• Zacks 14:00 Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?
• Zacks 13:39 ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
• Investing 11:58 Alkermes stock holds steady as H.C. Wainwright maintains Neutral rating
• Investor's Business Daily 17:29 Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
• Benzinga 17:29 Why Is Alkermes Stock Falling On Monday? - Alkermes (NASDAQ:ALKS)
• Investing 15:16 Alkermes stock falls after BofA maintains Neutral rating on narcolepsy drug
• Investing 11:46 Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data
• Investing 10:05 Alkermes narcolepsy drug shows positive results in phase 2 trial
• Investing 10:47 BlackRock increases stake in Alkermes to 17.05%
• Seeking Alpha 21:13 XPH: Healthcare Dashboard For July (NYSEARCA:XPH)